Preferential vasoconstriction to cysteinyl leukotrienes in the human saphenous vein compared with the internal mammary artery : implications for graft performance

• Published in: Circulation (New York, N.Y.) N.Y.), 1994-07, Vol.90 (1), p.515-524
• Main Authors: ALLEN, S. P, CHESTER, A. H, DASHWOOD, M. R, SAMAD TADJKARIMI, PIPER, P. J, YACOUB, M. H
• Format: Article
• Language: English
• Subjects: Adult; Aged; Autoradiography; Biological and medical sciences; Blood Vessel Prosthesis; Endothelium, Vascular - physiology; Humans; Indazoles - pharmacology; Leukotriene E4 - pharmacology; Leukotrienes - pharmacokinetics; Leukotrienes - pharmacology; Mammary Arteries - drug effects; Mammary Arteries - metabolism; Medical sciences; Middle Aged; Rest; Saphenous Vein - drug effects; Saphenous Vein - metabolism; SRS-A - antagonists & inhibitors; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Surgery of the heart; Vasoconstriction; Vasomotor System - drug effects
• ISSN: 0009-7322; 1524-4539
• DOI: 10.1161/01.CIR.90.1.515

Platelet aggregation with the release of their vasoactive mediators is an important factor contributing to the patency of coronary bypass grafts. However, the role of leukocyte-derived mediators on graft performance is unclear. Leukotrienes (LTs) are proinflammatory mediators released from a variety of leukocytes that possess both vasoactive and mitogenic properties. We have therefore compared the effects of the cysteinyl LTs (C4, D4, and E4) on the human saphenous vein (SV) and human internal mammary artery (IMA). Human SVs from 43 patients (mean age, 58 years) and IMAs from 33 patients (mean age, 57 years) were obtained from individuals undergoing coronary artery bypass surgery for coronary artery disease. The samples were set up in organ baths to record changes in vessel wall tension. In undistended SVs the cysteinyl LTs elicited concentration-dependent contractions. The Emax for LTE4 (4.23 +/- 1.0 mN; n = 6) was significantly less than that observed with either LTC4 (25.7 +/- 4.01 mN; n = 7; P < .001) or LTD4 (26.19 +/- 3.16 mN; n = 7; P < .001). In addition, the LTD4 receptor antagonist ICI 198615 (30 nmol/L) significantly inhibited the LTD4 concentration-response curve but not the LTC4 responses. Furthermore, treatment of the SV with acivicin (0.05 mmol/L), a gamma-glutamyl transpeptidase inhibitor, caused a significant rightward displacement of the LTC4 concentration-response curve. In contrast, LTC4 and LTD4 produced a response in IMAs from only 3 of 29 patients. LTC4 and LTD4 produced small contractions, of which the maximum responses were 3.28 +/- 1.92 mN (n = 5) and 3.12 +/- 1.38 mN (n = 5). LTE4 produced no responses in the IMA. Experiments in which the SV was pretreated with L-NG-monomethyl-L-arginine (L-NMMA; 10(-4) mol/L) or indomethacin (10(-5) mol/L) or was denuded of endothelium had no significant effect on the Emax values for LTE4. Also, the IMA remained unresponsive to cysteinyl leukotrienes after treatment with L-NMMA or indomethacin or endothelium removal. In vitro autoradiography localized specific [3H]-LTC4 and [3H]-LTD4 binding sites (putative receptors) to the smooth muscle cells of both SV and IMA, with greater binding to the SV. Our data show that there is a preferential contraction to LTs in SV compared with IMA. This difference in smooth muscle cell reactivity to the cysteinyl LTs suggests that endogenous LT production from circulating or infiltrating leukocytes may be an important factor contributing to graft function.